Research
No cure is currently available for Alzheimer’s Disease. At present, the few agents approved by the FDA and the clinical candidates have demonstrated only a modest effect, and none has shown a clear effect on disease progression or prevention. It is widely believed that the best treatment/prevention time window is at a presymptomatic stage, because the molecular pathological abnormality starts at about 5-15 years before the onset of the clinical symptoms. Clearly, early diagnosis of AD at its presymptomatic stage is tremendously desirable.
My research is structured to seek molecular imaging probes capable of detecting Amyloidosis (the most important molecular pathology of AD) within its full molecular pathological course. This process probably starts from imbalanced accumulation of amyloid beta (Ab) monomers, and ends with large plaques and neuron death. In order to achieve this goal, my research has been focused on the following aspects:
- Fluorescence Imaging Probe Development
- Multimodal imaging of Alzheimer’s disease
- Advanced Fluorescence Molecular Imaging Technologies for Alzheimer’s disease
- Drug Discovery for Alzheimer’s Disease